Company Dossier · Health Care
United Therapeutics
- Russell 1000
- MidCap 400
What United Therapeutics is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $3.15 billion, up 2.3% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $1.09 billion, up 1.9% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.59 billion, up 97% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $1.00 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 5, 2026): sentiment 0.10 on a −1 to +1 scale (mixed), confidence 0.60 of 1.Palanor Discourse
- Latest annual report (filed February 25, 2026): 0 risk factors added, 1 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $335 million on the open market.SEC Form 4
- 881 institutional managers reported a position at June 30, 2026 (+27 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 9 (7 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →Company Posture covers S&P 500 companies.
Credit
How these are built →No bond term sheets or tagged debt on file for United Therapeutics yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name United Therapeutics, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- PositiveUnited Therapeutics' legal victory; BMS' Camzyos approved for kids
Endpoints News · Oct 1, 2026
- NeutralCourt rules against Liquidia in United Therapeutics patent fight
Palanor Wire · Oct 1, 2026
- NeutralUnited Therapeutics (UTHR) Shares Surge 13% After Favorable Patent Ruling on Yutrepia
gurufocus.com · via Marketaux · Sep 30, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (TIBER CREEK GROUP)third_quarter 2026 · $0.1 million
- Sep 22, 2026Patent
- Sep 15, 2026Patent
- Sep 8, 20268-KMaterial agreement signedItem 1.01
- Aug 26, 2026Trademark
- Aug 18, 2026PatentPatent granted: SALTS OF TREPROSTINILUS 12709592
- Aug 4, 2026Patent
- Jul 23, 20268-KDirector or officer changeItem 5.02
- Jul 19, 2026LobbyingLobbying report (TIBER CREEK GROUP)second_quarter 2026 · $0.1 million
- Jun 29, 20268-KDirector or officer changeItem 5.02
- Jun 29, 20268-KShareholder vote resultsItem 5.07
- Jun 2, 2026Patent
- Apr 19, 2026LobbyingLobbying report (TIBER CREEK GROUP)first_quarter 2026 · $0.1 million
- Mar 26, 2026Trademark
- Mar 9, 20268-KMaterial agreement signedItem 1.01
- Feb 26, 2026Trademark
- Feb 26, 2026Trademark
- Feb 26, 2026Trademark
- Feb 25, 202610-KAnnual report (10-K)0 risk factors added, 1 removed
- Jan 22, 20268-KDirector or officer changeItem 5.02
- Jan 18, 2026LobbyingLobbying report (TIBER CREEK GROUP)fourth_quarter 2025 · $0.1 million
- Oct 19, 2025LobbyingLobbying report (TIBER CREEK GROUP)third_quarter 2025 · $0.0 million
- Oct 16, 2025LobbyingLobbying report (TIBER CREEK GROUP)third_quarter 2025
- Aug 1, 20258-KMaterial agreement signedItem 1.01
- Jun 27, 20258-KDirector or officer changeItem 5.02
- Jun 27, 20258-KShareholder vote resultsItem 5.07
- Apr 28, 20258-KMaterial agreement signedItem 1.01
- Apr 28, 20258-KMaterial agreement terminatedItem 1.02
- Feb 26, 202510-KAnnual report (10-K)0 risk factors added, 0 removed
- Feb 21, 202410-KAnnual report (10-K)1 risk factors added, 0 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Neurocrine Biosciences NBIX | $3.4B | $0.6B | Jun 30, 2026 |
| Exelixis EXEL | $2.4B | $1.2B | Jul 3, 2026 |
| Moderna MRNA | $2.2B | −$1.2B | Jun 30, 2026 |
| Incyte INCY | $5.4B | — | Mar 31, 2026 |
| Halozyme HALO | $1.7B | $0.8B | Jun 30, 2026 |
| Insmed INSM | $1.1B | −$0.8B | Jun 30, 2026 |
| Biogen BIIB | $9.9B | $2.4B | Mar 31, 2026 |
| Caris Life Sciences CAI | $1.0B | $0.1B | Jun 30, 2026 |
Identity
- SEC CIK
- 1082554